Psoriasis Clinical Trial

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

Summary

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study evaluates adverse events and change in disease activity with risankizumab in pediatric participants with moderate to severe plaque psoriasis who completed the study M19-977.

Risankizumab is an approved drug for treatment of moderate to severe plaque psoriasis in adults and is being studied in the pediatric population (6 to 17 years). A maximum of 132 participants will be enrolled in the study across approximately 50 sites worldwide.

Participants will receive subcutaneous injection of risankizumab every 12 weeks for 204 weeks and are followed up for safety for 20 weeks after last dose.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

--Participants who have completed participation in study M19-977 and who meet all eligibility criteria for participation in Study M19-973 will be allowed to enroll in study M19-973.

Exclusion Criteria:

--Participants who have developed any discontinuation criteria as defined in Study M19-977.

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

132

Study ID:

NCT04862286

Recruitment Status:

Enrolling by invitation

Sponsor:

AbbVie

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 37 Locations for this study

See Locations Near You

First OC Dermatology /ID# 226942
Fountain Valley California, 92708, United States
Integrative Skin Science and Research /ID# 226108
Sacramento California, 95815, United States
Solutions Through Adv Rch /ID# 226104
Jacksonville Florida, 32256, United States
Olympian Clinical Research- St. Petersburg /ID# 226106
Saint Petersburg Florida, 33709, United States
Advanced Clinical Research Institute /ID# 248827
Tampa Florida, 33607, United States
University Dermatology and Vein Clinic, LLC /ID# 226100
Darien Illinois, 60561, United States
Arlington Dermatology /ID# 226097
Rolling Meadows Illinois, 60008, United States
Skin Cancer and Dermatology Institute (SCDI) /ID# 248828
Reno Nevada, 89052, United States
Univ Hosp Cleveland /ID# 248825
Cleveland Ohio, 44106, United States
Apex Dermatology & Skin Surgery Center /ID# 248830
Mayfield Heights Ohio, 44124, United States
Medical University of South Carolina /ID# 248831
Charleston South Carolina, 29425, United States
Dermatology Research Institute Inc. /ID# 233988
Calgary Alberta, T2J 7, Canada
Karma Clinical Trials /ID# 233985
St. John's Newfoundland and Labrador, A1A 4, Canada
Hospital for Sick Children /ID# 233986
Toronto Ontario, M5G 1, Canada
CHU Sainte-Justine /ID# 233987
Montreal Quebec, H3T 1, Canada
Universitaetsklinikum Muenster /ID# 243905
Muenster Nordrhein-Westfalen, 48149, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 243883
Kiel Schleswig-Holstein, 24105, Germany
Fachklinik Bad Bentheim /ID# 243904
Bad Bentheim , 48455, Germany
Universitaetsklinikum Bonn /ID# 243910
Bonn , 53127, Germany
Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 243908
Dresden , 01307, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 243907
Mainz , 55131, Germany
Nagoya City University Hospital /ID# 248429
Nagoya shi Aichi, 467-8, Japan
Dermed Centrum Medyczne Sp. z o.o /ID# 243847
Lodz Lodzkie, 90-26, Poland
Dermoklinika Medical Center /ID# 243848
Lodz Lodzkie, 90-43, Poland
High-Med Przychodnia Specjalistyczna /ID# 243846
Warszawa Mazowieckie, 01-81, Poland
KSW nr1 w Rzeszowie /ID# 243850
Rzeszow Podkarpackie, 35-05, Poland
Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 243849
Gdansk Pomorskie, 80-54, Poland
Hospital Sant Joan de Deu /ID# 241103
Esplugues de Llobregat Barcelona, 08950, Spain
Hospital General Universitario Gregorio Maranon /ID# 241099
Madrid , 28007, Spain
Hospital Universitario Infanta Leonor /ID# 241100
Madrid , 28031, Spain
Hospital Universitario 12 de Octubre /ID# 241102
Madrid , 28041, Spain
Complejo Hospitalario Universitario de Pontevedra /ID# 241101
Pontevedra , 36071, Spain
Royal Devon University Healthcare NHS Foundation Trust /ID# 245101
Exeter Devon, EX2 5, United Kingdom
Guys and St Thomas NHS Foundation Trust /ID# 245100
London London, City Of, SE1 9, United Kingdom
Frimley Health NHS Foundation Trust /ID# 245105
Camberley , GU16 , United Kingdom
Chelsea and Westminster Hospital NHS Foundation Trust /ID# 245102
London , SW10 , United Kingdom
University Hospital Plymouth NHS Trust /ID# 245104
Plymouth , PL6 5, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

132

Study ID:

NCT04862286

Recruitment Status:

Enrolling by invitation

Sponsor:


AbbVie

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.